Introduction: Central centrifugal cicatricial alopecia (CCCA) is a progressive scarring alopecia. No disease activity scale exists, making assessment of therapeutic intervention difficult. This study introduces the CCCA Clinical Assessment Tool (C-CAT), a novel scale that quantifies symptom severity to facilitate tailored treatment and track disease progression. Methods: A retrospective review of patients with CCCA was assessed on degree of pruritus, erythema, pain, disease progression, and scalp resistance, each scored from 0 to 2, over the course of a minimum of 6 months of therapy. Results: Eighty-two patients were included. The average initial C-CAT score was 3.4, consistent with mild to moderate disease activity. After 6 months of treatment, 88% of patients had improvement in score, with 48% of all patients achieving remission. Intralesional kenalog injections and topical clobetasol were the most commonly used therapies. Patients required an average of 3.6 different treatments to achieve therapeutic response. Conclusion: The C-CAT provides a structured, quantitative method to assess CCCA severity, which facilitates tracking of disease improvement for the majority of patients with targeted therapy. While the subjective nature of some C-CAT components may lead to inter-rater variability, this tool promotes personalized, symptom-based treatment and supports clinicians and patients in understanding this complex condition.

1.
Ogunleye
TA
,
McMichael
A
,
Olsen
EA
.
Central centrifugal cicatricial alopecia: what has been achieved, current clues for future research
.
Dermatol Clin
.
2014
;
32
(
2
):
173
81
.
2.
Chiang
C
,
Sah
D
,
Cho
BK
,
Ochoa
BE
,
Price
VH
.
Hydroxychloroquine and lichen planopilaris: efficacy and introduction of lichen planopilaris activity Index scoring system
.
J Am Acad Dermatol
.
2010
;
62
(
3
):
387
92
.
3.
Holmes
S
,
Ryan
T
,
Young
D
,
Harries
M
;
British Hair and Nail Society
.
Frontal Fibrosing Alopecia Severity Index (FFASI): a validated scoring system for assessing frontal fibrosing alopecia
.
Br J Dermatol
.
2016
;
175
(
1
):
203
7
.
4.
Jamerson
TA
,
Conover Talbot
C
,
Dina
Y
,
Kwatra
SG
,
Garza
LA
,
Aguh
C
.
Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes
.
Exp Dermatol
.
2022
;
31
(
5
):
789
93
.
5.
George
EA
,
Matthews
C
,
Roche
FC
,
Taylor
SC
.
Beyond the hot comb: updates in epidemiology, pathogenesis, and treatment of central centrifugal cicatricial alopecia from 2011 to 2021
.
Am J Clin Dermatol
.
2023
;
24
(
1
):
81
8
.
6.
Callender
VD
,
Kazemi
A
,
Young
CM
,
Chappell
JA
,
Sperling
LC
.
Safety and efficacy of clobetasol propionate 0.05% emollient foam for the treatment of central centrifugal cicatricial alopecia
.
J Drugs Dermatol
.
2020
;
19
(
7
):
719
24
.
7.
Roques
C
,
Téot
L
.
The use of corticosteroids to treat keloids: a review
.
Int J Low Extrem Wounds
.
2008
;
7
(
3
):
137
45
.
8.
Aguh
C
,
Dina
Y
,
Talbot
CC
,
Garza
L
.
Fibroproliferative genes are preferentially expressed in central centrifugal cicatricial alopecia
.
J Am Acad Dermatol
.
2018
;
79
(
5
):
904
12.e1
.
9.
Choi
JY
,
Piao
MS
,
Lee
JB
,
Oh
JS
,
Kim
IG
,
Lee
SC
.
Propionibacterium acnes stimulates pro-matrix metalloproteinase-2 expression through tumor necrosis factor-alpha in human dermal fibroblasts
.
J Invest Dermatol
.
2008
;
128
(
4
):
846
54
.
10.
Ishikawa
C
,
Tsuda
T
,
Konishi
H
,
Nakagawa
N
,
Yamanishi
K
.
Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes
.
Antimicrob Agents Chemother
.
2009
;
53
(
5
):
1760
5
.
11.
Gadre
A
,
Dyson
T
,
Lai
J
,
Aguh
C
.
Increased IL-1β in stratum corneum as a marker of inflammation among central centrifugal cicatricial alopecia patients with pruritus: an observational study
.
JAAD Int
.
2023
;
13
:
195
7
.
12.
Bin Saif
GA
,
McMichael
A
,
Kwatra
SG
,
Chan
YH
,
Yosipovitch
G
.
Central centrifugal cicatricial alopecia severity is associated with cowhage-induced itch
.
Br J Dermatol
.
2013
;
168
(
2
):
253
6
.
13.
Wu
M
,
Xu
H
,
Liu
J
,
Tan
X
,
Wan
S
,
Guo
M
, et al
.
Metformin and fibrosis: a review of existing evidence and mechanisms
.
J Diabetes Res
.
2021
;
2021
:
6673525
.
14.
Rangarajan
S
,
Bone
NB
,
Zmijewska
AA
,
Jiang
S
,
Park
DW
,
Bernard
K
, et al
.
Metformin reverses established lung fibrosis in a bleomycin model
.
Nat Med
.
2018
;
24
(
8
):
1121
7
.
15.
Herskovitz
I
,
Miteva
M
.
Central centrifugal cicatricial alopecia: challenges and solutions
.
Clin Cosmet Investig Dermatol
.
2016
;
9
:
175
81
.
16.
Roche
FC
,
Harris
J
,
Ogunleye
T
,
Taylor
SC
.
Association of type 2 diabetes with central centrifugal cicatricial alopecia: a follow-up study
.
J Am Acad Dermatol
.
2022
;
86
(
3
):
661
2
.
17.
Randolph
M
,
Tosti
A
.
Oral minoxidil treatment for hair loss: a review of efficacy and safety
.
J Am Acad Dermatol
.
2021
;
84
(
3
):
737
46
.
18.
Shao
S
,
Zhang
X
,
Duan
L
,
Fang
H
,
Rao
S
,
Liu
W
, et al
.
Lysyl hydroxylase inhibition by minoxidil blocks collagen deposition and prevents pulmonary fibrosis via TGF-β1/smad3 signaling pathway
.
Med Sci Monit
.
2018
;
24
:
8592
601
.
19.
O’Donoghue
M
,
Tharp
MD
.
Antihistamines and their role as antipruritics
.
Dermatol Ther
.
2005
;
18
(
4
):
333
40
.
20.
Zbiciak-Nylec
M
,
Brzezińska-Wcisło
L
,
Salwowska
N
.
The efficacy of antimalarial drugs in the therapy of selected forms of cicatricial alopecia
.
Postepy Dermatol Alergol
.
2021
;
38
(
2
):
302
9
.
You do not currently have access to this content.